US FDA declines to approve AbbVie's Parkinson's disease therapy-March 2024-www.financetom.com

US FDA declines to approve AbbVie's Parkinson's disease therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA declines to approve AbbVie's Parkinson's disease therapy

Jun 25, 2024 5:40 AM

June 25 (Reuters) - AbbVie ( ABBV ) said on Tuesday the

U.S. Food and Drug Administration has rejected the company's

marketing application for its therapy to treat motor

fluctuations in adults with advanced Parkinson's disease.

Previous page： BRIEF-Ll Flooring Signs Agreement With F9 Investments For Going-Concern Sale Of Business Next page：

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Ll Flooring Signs Agreement With F9 Investments For Going-Concern Sale Of Business

Sep 6, 2024

Sept 6 (Reuters) - LL Flooring Holdings Inc ( LLFLQ ): * LL FLOORING SIGNS AGREEMENT WITH F9 INVESTMENTS FOR GOING-CONCERN SALE OF BUSINESS * LL FLOORING HOLDINGS INC ( LLFLQ ) - F9 INVESTMENTS TO ACQUIRE 219 STORES AND OTHER ASSETS * LL FLOORING HOLDINGS INC ( LLFLQ ) - TO CLOSE 211 STORES WITH HILCO MERCHANT RESOURCES *...

Sep 6, 2024

...

Verizon to acquire Frontier in $20 billion deal to boost fiber network

Sep 6, 2024

(Reuters) -Verizon said on Thursday it would buy Frontier Communications in an all-cash deal valued at $20 billion, as the U.S. wireless carrier looks to boost its fiber network. Shares of Frontier Communications fell more than 9% in premarket trading. Verizon climbed about 1%. Verizon has offered $38.50 per Frontier share held, a premium of 37.3% to Frontier's closing price...

RH Likely to Miss Existing Financial Outlook, UBS Says

Sep 6, 2024

03:32 PM EDT, 09/06/2024 (MT Newswires) -- RH's (RH) has shown some improvement in terms of demand in Q2, but is unlikely to meet its existing outlook, UBS Securities said in a note emailed Friday. In this case, the company is likely to lower its prior guidance that called for a significant inflection in its business in the back half...